Business Wire

NY-REVBITS

22.5.2023 15:16:25 CEST | Business Wire | Press release

Share
RevBits Completes Development for its Privileged Access Management Solution to be Fully Deployable in a True Air Gapped Environment

RevBits announces that it has successfully completed the architectural development of its privileged access management solution for deployment in a true air gapped environment.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230522005003/en/

RevBits Privileged Access Management (RB/PAM) is an advanced access management solution that includes seven modules and extensive session logging that captures keystrokes and video. These unique access control capabilities and multi-module offerings reduce vendor relationship management efforts and increase access management safeguards.

RevBits PAM has two U.S. patents - a browser-based zero-knowledge encryption and authentication authority that extends to various hardware security solutions.

RevBits PAM modules:

Privileged Access Management - regulates access to critical resources, captures keystrokes, and video records all privileged sessions.

Privileged Session Management - provides keystroke and query logging for all sessions through the solution's Jump Server.

Password Management - extends authentication security with hardware security modules, USB tokens, smart cards, near-field communications, and RFID.

Service Account Management - scans and onboards service accounts and scheduled tasks for IIS web applications.

Key Management - allows users to easily generate and store encryption keys.

Certificate Management - reports all expired or soon-to-expire certificates and vulnerable implementations of SSL.

CI/CD Integration - the CI/CD module plugs into your current platform and unlocks the capabilities of secure secret management across the CI/CD lifecycle, allowing for easy management of CI/CD users, credentials, and assets.

Defining Air Gap:

Techopedia: "An air gap is a security measure that isolates a digital device component or private local area network (LAN) from other devices and networks, including the public internet. An air gap is also known as an air wall, and the strategy of using air gaps to protect critical data is also known as security by isolation.

Air gaps are used to protect critical computer systems and the data they store from malware, keyloggers, ransomware, and other types of unauthorized access. This strategy seeks to ensure the total isolation of a given system electromagnetically, electronically, and physically."

RevBits Privileged Access Management – our Air Gap capability:

Inside the air gap environment sit servers and assets critical to the organization. As important as it is to protect against malware and ransomware attacks, it is equally important to protect the data on those servers from malicious acts and theft in an air gap environment.

RevBits Privileged Access Management is fully featured in an air gapped environment allowing for complete server security and data protection. Server access is monitored through extensive session monitoring, including video recording and keystroke logging.

About RevBits

Established in 2018, RevBits is a comprehensive cybersecurity company dedicated to providing customers with superior protection and service. RevBits delivers protection against the most sophisticated cyber threats companies face by offering multiple advanced security capabilities that can be administered through a unified security platform. RevBits is headquartered in Mineola, NY, with offices in Princeton, NJ; Boston, MA; London, England; and Antwerp, Belgium. For more information please visit RevBits.

RevBit's complete solution suite offerings are RevBits Endpoint Security, RevBits Email Security, RevBits Privileged Access Management, RevBits Zero Trust Network, and RevBits Deception Technology. For customers running more than one RevBits solution, the administration is managed through RevBits Cyber Intelligence Platform, a unified, single-pane environment that curates, correlates, and alerts to threats while delivering intelligence for a quick administrative response. RevBits Cyber Intelligence Platform integrates with all common SIEMs.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230522005003/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

IEO and Laife Reply Join Forces to Digitalise the Biobank Through Artificial Intelligence10.2.2026 10:00:00 CET | Press release

The two partners launch “Bianca”, the first large-scale digitalisation initiative in Italy focused on histopathological samples, aimed at training AI algorithms to support pathologists’ diagnostic activities. The Pathology Division of the European Institute of Oncology (IEO) and Laife Reply, the Reply Group company specialised in AI and Big Data solutions for the healthcare sector, have entered into a collaboration to develop Bianca, the first project in Italy aimed at creating an AI-based digital biobank designed as an integral part of clinical diagnostic practice. The initiative is part of a broader technological innovation journey that structurally integrates research and development into routine diagnostic processes in pathology, transforming the traditional histopathological sample workflow into an end-to-end digital ecosystem. The complete digitalisation of histopathological and molecular diagnostic workflows aims to make analysis more efficient, scalable and reproducible, laying

OPEX® Corporation Introduces the Velo™ Series of Premium Desktop and High Production Document Scanners10.2.2026 10:00:00 CET | Press release

OPEX® Corporation, a global leader in Next Generation Automation providing innovative solutions for warehouse, document and mail automation, has announced the launch of its Velo™ Series powered by InoTec, a new class of premium desktop and free standing high production scanners. The OPEX Velo scanners are engineered to deliver exceptional performance, reliability and image quality and offer industry-standard TWAIN/ISIS connectivity to help simplify deployment into existing capture environments. These state-of-the-art scanners are ideal for service bureaus, government agencies, healthcare providers and enterprise capture operations. “The Velo Series powered by InoTec introduces an entirely new class of scanners to the OPEX portfolio, expanding the options available to both our current customers and organizations considering OPEX for the first time,” said Dann Worrell, President, Document and Mail Automation, OPEX. “By broadening our offerings, we can better align the right solution with

New ZOLL Zenix Monitor/Defibrillator Receives MDR Approval10.2.2026 10:00:00 CET | Press release

ZOLL®, an Asahi Kasei company that manufactures medical devices and related software solutions, announced today that Zenix®, the company’s most clinically advanced and easy-to-use professional monitor/defibrillator, is approved under the European Union (EU) Medical Device Regulation 2017/745, commonly referred to as EU MDR. The Zenix monitor/defibrillator is a groundbreaking device that redefines efficiency, clarity, and intelligence in both EMS and hospital settings. Built from years of feedback from customers, Zenix combines intuitive design with powerful functionality to enhance patient care and automate workflows for ease-of-use. Featuring a large, durable touchscreen, Zenix provides critical information when it’s needed. With on-the-fly customization, healthcare professionals can make real-time adjustments, helping them stay in control during high-pressure situations. Equipped with ZOLL’s innovative Real BVM Help® and exclusive Real CPR Help® technology, Zenix gives healthcare pro

Expereo Elevates expereoOne with New Digital Case Management Capabilities, Delivering Faster, Clearer and More Predictable Service Resolution10.2.2026 10:00:00 CET | Press release

Expereo is redefining what’s possible for global enterprises at CiscoLive Amsterdam with the launch of its enhanced Digital Case Management (DCM) capability in expereoOne. As the world-leading managed Network as a Service (NaaS) provider, Expereo is putting customers firmly in control - slashing resolution times, cutting through operational noise and ensuring everyone is aligned every step of the way. With DCM, service issues are no longer bottlenecks: instead, enterprises experience swift, transparent outcomes, with every stakeholder empowered through a single, real-time view of progress. DCM is designed around a simple objective: enable enterprises to resolve issues faster, with greater clarity and full control, through a fully digital, software-first workflow inside expereoOne. Customers can create, manage and track cases end-to-end within a single platform, ensuring predictable, consistent and aligned service experiences across their global network footprint. Unified, digital-first

U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Takeda’s Oveporexton (TAK-861) as a Potential First-in-Class Therapy for Narcolepsy Type 110.2.2026 09:15:00 CET | Press release

This FDA Acceptance is a Milestone for People Living with Narcolepsy Type 1 Who Need New and Different Treatment OptionsOveporexton is an Orexin Agonist Designed to Restore Orexin Signaling and Address the Underlying Orexin Deficiency that Causes Narcolepsy Type 1The Prescription Drug User Fee Act (PDUFA) Target Action Date is the Third Quarter of this Calendar Year Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) and granted Priority Review for oveporexton (TAK-861) for the treatment of narcolepsy type 1 (NT1). Oveporexton is an investigational oral orexin receptor 2 (OX2R)-selective agonist designed to address the underlying orexin deficiency that causes NT1 by restoring orexin signaling. The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date in the third quarter of this calendar year. Takeda remains on track to potentially bring the first approved orexin agonist treatment to people living

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye